Despite the availability of first- and second-generation tyrosine kinase inhibitors (TKIs), patients with chronic phase chronic myeloid leukemia (CP-CML) harboring the BCR::ABL1 T315I mutation continue to face poor survival outcomes, often due to the development of resistance.¹ Ponatinib, a third-generation TKI, has previously demonstrated significant efficacy in treating patients with CP-CML regardless of BCR::ABL1 mutation status.^2-4 At the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, Professor Michael Deininger presented key findings from the 4-year follow-up post-hoc analysis of the OPTIC trial, an open-label phase 2 study investigating the efficacy, safety and dose-response relationship of ponatinib in CP-CML patients with the difficult-to-treat T315I mutation.^2,5